Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NYESO-1c259 T cells · 1 trial · 1 indication
Number of Participants with Adverse Events related to study treatment
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells. |
| Name | Type | Description |
|---|---|---|
| NYESO-1c259 T cells | BIOLOGICAL | Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion. |
Inclusion Criteria: * Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum resistant disease and/or have received ≥ 2 lines of chemotherapy * Age ≥ 18 years of age * No significant immunodeficiency * Have been informed of ...
Top 20 of 59 competitors
NYESO-1c259 T cells is an investigational cell therapy being studied for the treatment of ovarian cancer. It is designed to target cancer cells expressing the NY-ESO-1 antigen. The therapy is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
NYESO-1c259 T cells targets the NY-ESO-1 cancer testis antigen, which is expressed on the surface of certain tumor cells. The therapy uses T cells engineered with a T cell receptor that recognizes this antigen, aiming to direct the immune system against cancer cells in ovarian cancer.
NYESO-1c259 T cells is being developed by Adaptimmune Therapeutics PLC, a biopharmaceutical company listed on the stock exchange under the ticker ADAP. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy for ovarian cancer.
NYESO-1c259 T cells is in Phase 1 clinical development. It is an investigational therapy and has not received regulatory approval. A Phase 1 clinical trial has been completed to assess its safety and preliminary activity in patients with ovarian cancer.
NYESO-1c259 T cells has been studied in a completed Phase 1 clinical trial with the identifier NCT01567891. The trial, titled 'CT Antigen TCR-redirected T Cells for Ovarian Cancer,' enrolled 9 participants in the United States and evaluated the therapy in patients with ovarian cancer.